<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Bausch + Lomb Corp — News on 6ix</title>
<link>https://6ix.com/company/bausch-lomb-corp</link>
<description>Latest news and press releases for Bausch + Lomb Corp on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/bausch-lomb-corp" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354de078dffbe2df0e620f.webp</url>
<title>Bausch + Lomb Corp</title>
<link>https://6ix.com/company/bausch-lomb-corp</link>
</image>
<item>
<title>Bausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular Degeneration</title>
<link>https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-announces-published-review-examining-the-role-of-b-vitamins-in-reducing-risk-and-progression-of-age-related-macular-degeneration</link>
<guid isPermaLink="true">https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-announces-published-review-examining-the-role-of-b-vitamins-in-reducing-risk-and-progression-of-age-related-macular-degeneration</guid>
<pubDate>Thu, 23 Apr 2026 11:00:00 GMT</pubDate>
<description>VAUGHAN, Ontario, April 23, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Ophthalmology and Therapy published a narrative review highlighting the role of certain B vitamins in reducing the risk of development and progression of AMD1, a leading cause of vision loss in Americans 50 years of age or older.2</description>
</item>
<item>
<title>Bausch + Lomb Releases 2025 Sustainability Impact Report</title>
<link>https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-releases-2025-sustainability-impact-report</link>
<guid isPermaLink="true">https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-releases-2025-sustainability-impact-report</guid>
<pubDate>Wed, 22 Apr 2026 11:15:00 GMT</pubDate>
<description>VAUGHAN, Ontario, April 22, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the release of its 2025 Sustainability Impact Report, outlining progress against its environmental, social and governance priorities and introducing The Broader Perspective, the company’s sustainability framework designed to guide future action and accountability.</description>
</item>
<item>
<title>Bausch + Lomb Reports Nearly 725,000 Pounds of Contact Lens, Lens Care and Eye Care Materials Collected and Recycled Through ONE By ONE Recycling Program</title>
<link>https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-reports-nearly-725000-pounds-of-contact-lens-lens-care-and-eye-care-materials-collected-and-recycled-through-one-by-one-recycling-program</link>
<guid isPermaLink="true">https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-reports-nearly-725000-pounds-of-contact-lens-lens-care-and-eye-care-materials-collected-and-recycled-through-one-by-one-recycling-program</guid>
<pubDate>Thu, 16 Apr 2026 11:00:00 GMT</pubDate>
<description>VAUGHAN, Ontario, April 16, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its one-of-a-kind ONE by ONE Recycling program, created in collaboration with international recycling leader TerraCycle®, has collected and recycled a total of 119,715,074 units, or 724,922 pounds, of used contact lenses, eye care and lens care materials in the United States – the equivalent of about five backyard</description>
</item>
<item>
<title>Bausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+™ Dual-Port Vitrectomy Cutter and Adaptive Fluidics™ Advanced Update</title>
<link>https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-receives-fda-510k-clearance-for-bi-bladetm-dual-port-vitrectomy-cutter-and-adaptive-fluidicstm-advanced-update</link>
<guid isPermaLink="true">https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-receives-fda-510k-clearance-for-bi-bladetm-dual-port-vitrectomy-cutter-and-adaptive-fluidicstm-advanced-update</guid>
<pubDate>Wed, 08 Apr 2026 11:00:00 GMT</pubDate>
<description>VAUGHAN, Ontario, April 08, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Bi-Blade+ advanced dual-port vitrectomy cutter and the Adaptive Fluidics advanced update on the Stellaris Elite® Vision Enhancement System.</description>
</item>
<item>
<title>Bausch + Lomb Launches Preloaded enVista Envy™ Full Range of Vision Intraocular Lenses in Europe</title>
<link>https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-launches-preloaded-envista-envytm-full-range-of-vision-intraocular-lenses-in-europe</link>
<guid isPermaLink="true">https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-launches-preloaded-envista-envytm-full-range-of-vision-intraocular-lenses-in-europe</guid>
<pubDate>Tue, 07 Apr 2026 11:00:00 GMT</pubDate>
<description>VAUGHAN, Ontario, April 07, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced European commercial availability of the preloaded enVista Envy full range of vision intraocular lens (IOL), which offers excellent dysphotopsia tolerance on the widely used enVista IOL platform.</description>
</item>
<item>
<title>Bausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual Meeting</title>
<link>https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-announces-new-scientific-data-educational-events-at-the-american-society-of-cataract-and-refractive-surgery-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-announces-new-scientific-data-educational-events-at-the-american-society-of-cataract-and-refractive-surgery-annual-meeting</guid>
<pubDate>Mon, 06 Apr 2026 11:00:00 GMT</pubDate>
<description>VAUGHAN, Ontario, April 06, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of new scientific data and events taking place during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Washington, D.C., April 10-13, 2026.</description>
</item>
<item>
<title>Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29</title>
<link>https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-will-release-first-quarter-2026-financial-results-on-april-29</link>
<guid isPermaLink="true">https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-will-release-first-quarter-2026-financial-results-on-april-29</guid>
<pubDate>Mon, 30 Mar 2026 11:15:00 GMT</pubDate>
<description>VAUGHAN, Ontario, March 30, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 29, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the ca</description>
</item>
<item>
<title>Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma</title>
<link>https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-announces-positive-24-month-us-data-on-the-eliostm-system-for-treatment-of-glaucoma</link>
<guid isPermaLink="true">https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-announces-positive-24-month-us-data-on-the-eliostm-system-for-treatment-of-glaucoma</guid>
<pubDate>Mon, 23 Mar 2026 11:00:00 GMT</pubDate>
<description>VAUGHAN, Ontario, March 23, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced positive 24-month results from the pivotal U.S. clinical trial of the ELIOS System. Developed for the treatment of elevated intraocular pressure (IOP) in patients with open angle glaucoma, ELIOS is an implant-free procedure that uses next generation excimer laser technology. The ELIOS procedure is currently CE mar</description>
</item>
<item>
<title>Bausch + Lomb Launches R&D "Teach-in" Webinar Series</title>
<link>https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-launches-randd-teach-in-webinar-series</link>
<guid isPermaLink="true">https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-launches-randd-teach-in-webinar-series</guid>
<pubDate>Mon, 09 Mar 2026 11:15:00 GMT</pubDate>
<description>VAUGHAN, Ontario, March 09, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the first event in an R&D "Teach-in" webinar series that will provide deeper insights on the company’s differentiated product pipeline, which was unveiled in November 2025.</description>
</item>
<item>
<title>Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®</title>
<link>https://6ix.com/company/bausch-lomb-corp/news/ophthalmology-and-therapy-publishes-findings-showing-lifestyle-driven-rise-in-ocular-redness-and-differentiated-role-of-lumifyr</link>
<guid isPermaLink="true">https://6ix.com/company/bausch-lomb-corp/news/ophthalmology-and-therapy-publishes-findings-showing-lifestyle-driven-rise-in-ocular-redness-and-differentiated-role-of-lumifyr</guid>
<pubDate>Tue, 24 Feb 2026 12:00:00 GMT</pubDate>
<description>VAUGHAN, Ontario, February 24, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, announced today that Ophthalmology and Therapy published a new global narrative review examining the causes, burden and management of noninfectious conjunctival hyperemia (ocular redness). The review highlights the growing global prevalence of ocular redness driven by digital lifestyles, dry eye, contact lens wear, allergies a</description>
</item>
<item>
<title>Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance</title>
<link>https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-announces-fourth-quarter-and-full-year-2025-results-provides-2026-guidance</link>
<guid isPermaLink="true">https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-announces-fourth-quarter-and-full-year-2025-results-provides-2026-guidance</guid>
<pubDate>Wed, 18 Feb 2026 11:58:00 GMT</pubDate>
<description>VAUGHAN, Ontario, February 18, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full-year 2025 financial results.</description>
</item>
<item>
<title>Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference</title>
<link>https://6ix.com/company/bausch-lomb-corp/news/bausch-health-to-participate-in-the-jp-morgan-global-leveraged-finance-conference-1</link>
<guid isPermaLink="true">https://6ix.com/company/bausch-lomb-corp/news/bausch-health-to-participate-in-the-jp-morgan-global-leveraged-finance-conference-1</guid>
<pubDate>Tue, 17 Feb 2026 12:00:00 GMT</pubDate>
<description>Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that Executive Vice President and CFO Jean-Jacques (JJ) Charhon, along with other management team members, will attend the J.P. Morgan Global Leveraged Finance Conference in Miami Beach, Florida, from March 2–4, 2026, to meet with investors.</description>
</item>
<item>
<title>Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18</title>
<link>https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-release-fourth-quarter-121500302</link>
<guid isPermaLink="true">https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-release-fourth-quarter-121500302</guid>
<pubDate>Tue, 20 Jan 2026 12:15:00 GMT</pubDate>
<description>VAUGHAN, Ontario, January 20, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2025 financial results on Wednesday, Feb. 18, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior t</description>
</item>
<item>
<title>Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.</title>
<link>https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-partners-glaucoma-research-120000638</link>
<guid isPermaLink="true">https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-partners-glaucoma-research-120000638</guid>
<pubDate>Mon, 05 Jan 2026 12:00:00 GMT</pubDate>
<description>VAUGHAN, Ontario, January 05, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, is launching its fifth annual fundraising challenge with Glaucoma Research Foundation (GRF) during Glaucoma Awareness Month in January. Bausch + Lomb will also sponsor The Glaucoma Foundation’s (TGF) social media campaign to raise awareness of the disease and its impact by highlighting a glaucoma patient or advocate every day i</description>
</item>
<item>
<title>Bausch + Lomb Completes Refinancing of Outstanding Term B Loans</title>
<link>https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-completes-refinancing-outstanding-213000641</link>
<guid isPermaLink="true">https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-completes-refinancing-outstanding-213000641</guid>
<pubDate>Fri, 02 Jan 2026 21:30:00 GMT</pubDate>
<description>VAUGHAN, Ontario, January 02, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "company"), a leading global eye health company dedicated to helping people see better to live better, today announced that it closed the previously announced credit agreement refinancing. In connection with the closing, Bausch + Lomb has entered into a fourth amendment (the "Fourth Amendment") to its existing credit agreement providing for a $2,802,125,000 tranche (the "Replacement Term Loans"</description>
</item>
<item>
<title>Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-participate-44th-annual-123000341</link>
<guid isPermaLink="true">https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-participate-44th-annual-123000341</guid>
<pubDate>Tue, 23 Dec 2025 12:30:00 GMT</pubDate>
<description>VAUGHAN, Ontario, December 23, 2025--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders, Executive Vice President and Chief Financial Officer Sam Eldessouky and Chief Medical Officer and Head of Research & Development Yehia Hashad, MD, will participate in a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026, at 1:</description>
</item>
<item>
<title>Bausch + Lomb Announces Two Board of Directors Appointments</title>
<link>https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-announces-two-board-213000268</link>
<guid isPermaLink="true">https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-announces-two-board-213000268</guid>
<pubDate>Wed, 17 Dec 2025 21:30:00 GMT</pubDate>
<description>VAUGHAN, Ontario, December 17, 2025--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Eduardo C. Alfonso, MD, and Steven H. Collis have been appointed to its board of directors. The appointments are effective Jan. 1, 2026, and following changes announced in August 2025 the board will be comprised of 10 directors.</description>
</item>
<item>
<title>Bausch + Lomb Announces Refinancing of Outstanding Term B Loans</title>
<link>https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-announces-refinancing-outstanding-214800980</link>
<guid isPermaLink="true">https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-announces-refinancing-outstanding-214800980</guid>
<pubDate>Fri, 12 Dec 2025 21:48:00 GMT</pubDate>
<description>VAUGHAN, Ontario, December 12, 2025--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "company"), a leading global eye health company dedicated to helping people see better to live better, today announced that it allocated a $2,802,125,000 tranche (the "Replacement Term Loans") of new term B loans, the proceeds of which will be used to refinance all of its outstanding term B loans due 2031 (the "Third Amendment Term Loans") and its outstanding term B loans due 2028 (the "First</description>
</item>
<item>
<title>Bausch + Lomb to Participate in Citi Global Healthcare Conference</title>
<link>https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-participate-citi-global-213000592</link>
<guid isPermaLink="true">https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-participate-citi-global-213000592</guid>
<pubDate>Tue, 18 Nov 2025 21:30:00 GMT</pubDate>
<description>VAUGHAN, Ontario, November 18, 2025--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders and Executive Vice President and Chief Financial Officer Sam Eldessouky will participate in a fireside chat at the 2025 Citi Global Healthcare Conference on Wednesday, Dec. 3, 2025, at 9:00 a.m. ET.</description>
</item>
<item>
<title>Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day</title>
<link>https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-highlight-company-transformation-120000811</link>
<guid isPermaLink="true">https://6ix.com/company/bausch-lomb-corp/news/bausch-lomb-highlight-company-transformation-120000811</guid>
<pubDate>Thu, 13 Nov 2025 12:00:00 GMT</pubDate>
<description>VAUGHAN, Ontario, November 13, 2025--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will outline the next chapter of its evolution today during an investor day event at the New York Stock Exchange.</description>
</item>
</channel>
</rss>